Psychemedics (PMDI) 10-K 28 Mar 24 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Mar. 25, 2024	Jun. 30, 2023
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	1-13738
Entity Registrant Name	PSYCHEMEDICS CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	58-1701987
Entity Address, Address Line One	5220 Spring Valley Road
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75254
City Area Code	800
Local Phone Number	527-7424
Title of 12(b) Security	Common stock. $0.005 par value
Trading Symbol	PMD
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 22.1
Entity Common Stock, Shares Outstanding (in shares)		5,805,611
Auditor Firm ID	243
Auditor Name	BDO USA, P.C.
Auditor Location	Boston, Massachusetts
Entity Central Index Key	0000806517
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash	$ 1,964	$ 4,750
Accounts receivable, net of allowance for credit losses of $64 and $87 at December 31, 2023 and 2022, respectively	3,687	3,739
Prepaid expenses and other current assets	1,136	1,136
Income tax receivable	18	339
Total Current Assets	6,805	9,964
Property and equipment:
Computer software	4,774	4,648
Office furniture and equipment	2,253	2,247
Laboratory equipment	16,038	16,013
Leasehold improvements	3,629	3,629
Property, Plant and Equipment, Gross	26,694	26,537
Accumulated depreciation and amortization	(23,633)	(21,964)
Property, Plant and Equipment, Net	3,061	4,573
Other assets	632	823
Deferred tax assets	0	691
Operating lease right-of-use assets	1,828	2,681
Total Assets	12,326	18,732
Current Liabilities:
Accounts payable	752	448
Accrued expenses	2,604	3,939
Current portion of long-term debt	305	294
Current portion of operating lease liabilities	1,048	1,037
Total Current Liabilities	4,709	5,718
Long-term debt	0	305
Long-term portion of operating lease liabilities	945	1,938
Total Liabilities	5,654	7,961
Commitments and Contingencies
Shareholders' Equity:
Preferred stock, $0.005 par value, 873 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.005 par value; 50,000 shares authorized 6,474 shares and 6,349 shares issued at December 31, 2023 and 2022, respectively, 5,806 shares outstanding and 5,681 shares outstanding at December 31, 2023 and 2022, respectively	32	32
Additional paid-in capital	35,129	34,275
Less - Treasury stock, at cost, 668 shares	(10,082)	(10,082)
Accumulated deficit	(16,773)	(11,820)
Accumulated other comprehensive loss	(1,634)	(1,634)
Total Shareholders' Equity	6,672	10,771
Total Liabilities and Shareholders' Equity	$ 12,326	$ 18,732

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accounts Receivable, Allowance for Credit Loss, Current	$ 64	$ 87
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.005	$ 0.005
Preferred Stock, Shares Authorized (in shares)	873	873
Preferred Stock, Shares Issued (in shares)	0	0
Preferred Stock, Shares Outstanding (in shares)	0	0
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.005	$ 0.005
Common Stock, Shares Authorized (in shares)	50,000	50,000
Common Stock, Shares, Issued (in shares)	6,474	6,349
Common Stock, Shares, Outstanding (in shares)	5,806	5,681
Treasury Stock, Common, Shares (in shares)	668	668

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 22,098	$ 25,240
Cost of revenues	13,685	15,949
Gross profit	8,413	9,291
Operating Expenses:
General & administrative	7,192	5,857
Marketing & selling	2,998	3,191
Research & development	1,144	1,326
Total Operating Expenses	11,334	10,374
Operating (loss) income	(2,921)	(1,083)
Other Income (Expense):
Settlements	507	0
Other income (expense)	(10)	43
Total Other Income (Expense)	(517)	43
Net loss before provision for (benefit from) income taxes	(3,438)	(1,040)
Provision for (benefit from) income taxes	716	44
Net loss and comprehensive loss	$ (4,154)	$ (1,084)
Basic and diluted net loss per share (in dollars per share)	$ (0.72)	$ (0.19)
Weighted average common shares outstanding
Basic (in shares)	5,740	5,626
Diluted (in shares)	5,740	5,626

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
BALANCE (in shares) at Dec. 31, 2021	6,257		668
BALANCE at Dec. 31, 2021	$ 31	$ 33,478				$ 12,243
Shares issued – vested (in shares)	91					0
Shares issued – vested	$ 1	(1)
Exercise of stock options (in shares)	1		0
Exercise of stock options	$ 0	4	$ 0	$ 0	$ 0	$ 4
Tax withholding related to vested shares from employee stock plans	0	(78)	0	0	0
Stock compensation expense		872				$ 872
Common Stock, Dividends, Per Share, Declared (in dollars per share)						$ 0.14
Cash dividends declared	0	0	0	(1,186)	0	$ (1,186)
Net loss	$ 0	0	$ 0	(1,084)	0	(1,084)
BALANCE (in shares) at Dec. 31, 2022	6,349		668
BALANCE at Dec. 31, 2022	$ 32	34,275	$ (10,082)	(11,820)	(1,634)	10,771
Shares issued – vested (in shares)	125		0
Tax withholding related to vested shares from employee stock plans	$ 0	(54)	$ 0	0	0	(54)
Stock compensation expense	0	908	0	0	0	908
Cash dividends declared	0	0	0	(799)	0	(799)
Net loss	$ 0	0	$ 0	(4,154)	0	(4,154)
BALANCE (in shares) at Dec. 31, 2023	6,474		668
BALANCE at Dec. 31, 2023	$ 32	$ 35,129	$ (10,082)	$ (16,773)	$ (1,634)	$ 6,672

Consolidated Statements of Sh_2

Consolidated Statements of Shareholders' Equity (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2020
Common Stock, Dividends, Per Share, Declared (in dollars per share)	$ 0.14	$ 0.21

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (4,154)	$ (1,084)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	1,731	2,367
ROU asset amortization	939	949
Deferred income taxes	691	(531)
Stock compensation expense	908	872
Loss on disposal of patents	131	0
Changes in operating assets and liabilities:
Accounts receivable	52	377
Prepaid expenses and other current assets	0	363
Income tax receivable	321	2,339
Accounts payable	304	(546)
Operating lease liabilities	(1,068)	(967)
Accrued expenses	(1,335)	751
Net cash provided by (used in) operating activities	(1,480)	4,890
Cash flows from investing activities:
Purchases of other assets	(2)	(21)
Purchases of property and equipment and capitalized software development costs	(157)	(187)
Net cash used in investing activities	(159)	(208)
Cash dividends paid	799	1,186
Proceeds from stock options and tax withholding related to vested shares from employee stock plans	(54)	(74)
Payments of equipment financing	(294)	(664)
Net cash used in financing activities	(1,147)	(1,924)
Net increase (decrease) in cash	(2,786)	2,758
Cash, beginning of year	4,750	1,992
Cash, end of year	1,964	4,750
Cash paid for operating leases	1,167	1,044
Cash paid for interest	18	33
Right-of-use assets acquired through operating leases	$ 86	$ 78

Note 1 - Nature of Business

Note 1 - Nature of Business	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Nature of Business Company Overview Psychemedics Corporation (the “Company,” ”we,” “us,” or “our”) provides hair testing for drugs of abuse, utilizing a patented hair analysis method involving digestion of hair, enzyme immunoassay and mass spectrometry to analyze hair to detect abused substances. Our customers include Fortune 500 companies, as well as small to mid-size corporations, schools and governmental entities located in the United States and Internationally. Liquidity and Management s Plans At December 31, 2023, our principal sources of liquidity from operations included $2.0 million of cash on hand. As of the date of this report, management currently believes that such funds, together with future operating profits, should be adequate to fund anticipated working capital requirements, including debt obligations, and capital expenditures for at least the next 12 months. However, the terms of our existing equipment financing no longer provide for future borrowings and we have no existing line of credit or other fixed source of capital reserves. Depending upon our results of operations, our future capital needs and available marketing opportunities, we may be required to seek various financing sources to raise additional funds. Such sources could include but are not limited to, issuance of common stock or debt financing, lines of credit, equipment leasing or a strategic transaction; although there is no assurance that such financings will be available to us on terms we deem acceptable, if at all. If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations would be materially adversely affected.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Risks and Uncertainties We are subject to a number of risks and uncertainties similar to those of other companies, such as those associated with the continued expansion of our sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered by us, the economic health of our principal customers , financial and operational risks associated with expansion of testing facilities we use, government regulation (including, but not limited to, FDA regulations, proposed laws and regulations, and delays in implementation of laws and regulations), competition and general economic conditions. Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates, including those related to bad debts, long-lived asset lives, income tax valuation and share based compensation, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. Cash and Cash Equivalents We consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents. As of December 31, 2023, and 2022, there were no Property and Equipment Property & equipment are recorded at cost. Depreciation and amortization is computed over the estimated useful lives of the assets, using the straight-line method. Repair and maintenance costs are expensed as incurred. The estimated useful lives of the assets are: Computer software 3 to 5 years Office furniture and equipment 3 to 7 years Laboratory equipment 5 to 7 years Leasehold improvements Lesser of estimated useful life or lease term We recorded depreciation and amortization related to property and equipment and capitalized software of $1.7 million, $2.4 million in 2023 and 2022, respectively. We had $613 thousand of capitalized software and equipment that was not placed in service as of December 31, 2023, which is included as a component of computer software on the accompanying consolidated balance sheets. Capitalized Software Development Costs We capitalize costs related to significant software projects developed or obtained for internal use, including costs incurred in a cloud computing arrangement. Costs incurred during the preliminary project work stage or conceptual stage, such as determining the performance requirements, system requirements and data conversion, are expensed as incurred. Costs incurred in the application development phase, such as coding, testing for new software and upgrades that result in additional functionality, are capitalized and are amortized using the straight-line method over the useful life of the software for three five Other Assets Other assets primarily consist of capitalized legal costs relating to patent applications. We amortize these costs over the lesser of the legal life or estimated useful life of the patent from the date of grant of the applicable patent. The typical life is twenty Allowance for Credit Losses The allowance for credit losses is based on management’s assessment of the ability to collect amounts owed to us by our customers. Management reviews the collectability of our accounts receivable and establishes an allowance for estimated losses that could result from the inability of our customers to make required payments, taking into consideration customer credit history and financial condition, industry and market segment information, credit reports, and economic trends and conditions. We maintain an allowance for potential credit losses but historically has not experienced any significant losses related to individual customers or groups of customers in any particular industry or geographic area. Revenue Recognition We are in the business of performing drug testing services and reporting the results thereof. Our services are primarily drug and alcohol testing for our customers for an agreed-upon fee per unit tested. The revenues are recognized when the drug test is performed and reported to the customer. Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration (none of which is variable) we expect to be entitled to in exchange for those services. We typically invoice customers monthly for services provided and payments are generally due within 30 to 60 days of the invoice date. The table below disaggregates our external revenue by major source (in thousands). For additional revenue detail relating to geographic breakdown of sales, see Note 13 – “Business Segment Reporting” to the Consolidated Financial Statements included in this Annual Report. Year Ended December 31, 2023 2022 Consolidated Revenue: Testing $ 18,661 $ 21,608 Shipping / Collection (hair) 3,316 3,476 Other 121 156 Total Revenue $ 22,098 $ 25,240 Testing Revenue Drug and alcohol tests for drugs of abuse using hair, performed in our forensic laboratory in California, represents our primary service. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (“CCF”) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer. Most tests are completed the same day that the hair specimen is received. Substantially all tests are completed within a few days once received for processing at our laboratory in California. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue. Revenue is measured as the amount of consideration we expect to receive in exchange for providing services. Sales taxes we pay concurrent with revenue-producing activities are excluded from revenue. Shipping and Hair Collection Revenue Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (collectively called the “sample”) to our laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by third parties who we have contracted with. Shipping and hair collection revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test (associated with the shipping or hair collection charge) and availability of test results to the customer. Revenue is measured as the amount of consideration we expect to receive in exchange for providing services. As we control the service before transferring to the customer, we are considered a principal in the transaction, and therefore record revenues on a gross basis, with shipping and hair collection costs in costs of revenues. Other Revenue Other revenue represents several items including: urine testing performed by other labs, medical review officer charges, legal/testifying services, and other miscellaneous charges. The total of all these items is less than 1% of total revenue. The amounts are generally billed to customers as services are performed, which occurs at a specific point-in-time. Practical Expedients and Exemptions We generally expense sales commissions when incurred as they are typically not related to costs to fulfill customer contracts but relate to overall sales targets. These costs are recorded within marketing and selling expense on the accompanying consolidated statements of operations. Research and Development Expenses We expense all research and development costs as incurred. Contingencies Loss contingencies from legal proceedings and claims may occur from government investigations, shareholder lawsuits, product liability, contractual claims, tax and other matters. Accruals are recognized when it is probable a liability will be incurred, and the amount of loss can be reasonably estimated. Legal fees are expensed as incurred. Income Taxes We account for income taxes using the liability method pursuant to ASC 740, “ Income Taxes Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that potentially subject us to concentrations of credit risk are principally cash and accounts receivable. Our policy is to place our cash in high quality financial institutions. At times, including presently, these deposits may exceed or be exempt from federally insured limits. We do not believe significant credit risk exists with respect to these institutions. Concentration of credit risk with respect to accounts receivable is limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses but historically have not experienced any significant losses related to individual customers or groups of customers in any particular industry or geographic area. We do not require collateral. We have no significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Significant Customers and Concentration of Credit Risk We had no two one Stock-Based Compensation We account for equity awards in accordance with ASC 718, “ Compensation Stock Compensation Stock compensation expense by statements of operations account is as follows (in thousands): Year Ended December 31, 2023 2022 Cost of revenues $ 40 $ 63 General & administrative 756 626 Marketing & selling 47 113 Research & development 65 70 Total stock compensation $ 908 $ 872 See Note 7 – “Stock-Based Awards” to the Consolidated Financial Statements included in this Annual Report for additional information relating to our stock plan. Basic and Diluted Net Loss per Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares and dilutive common stock equivalents outstanding during the period. The number of dilutive common stock equivalents outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and the unvested portion of stock unit awards (“SUAs”). Basic and diluted weighted average common shares outstanding are as follows (in thousands): 2023 2022 Weighted average common shares outstanding, basic 5,740 5,626 Dilutive common equivalent shares - - Weighted average common shares outstanding, assuming dilution 5,740 5,626 For the years ended December 31, 2023, and 2022, options to purchase 512 thousand and 508 thousand common shares were outstanding but not included in the dilutive common equivalent share calculation as their effect would have been anti-dilutive. The following outstanding common stock equivalents were not included in the dilutive common equivalent share calculation as their effect would have been anti-dilutive (in thousands): 2023 2022 Options 512 508 SUAs 140 238 652 746 Fair Value Measurements The fair values of cash, accounts receivable and accounts payable approximate their carrying values due to their short maturities. The carrying value of long term debt approximates its fair value, as it is based on current market rates at which we could borrow funds with similar terms. Basis of Preparation and Consolidation The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries and have been prepared using accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany transactions and balances have been eliminated. Segment Reporting We manage our operations as one segment, drug testing services. As a result, the financial information disclosed herein materially represents all of the financial information related to our principal operating segment. See Note 13 – “Business Segment Reporting” to the Consolidated Financial Statements included in this Annual Report for geographic breakdown of revenue. Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update No. 2016-13, Financial Instruments Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, among other provisions. The ASU is effective for fiscal year periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the ASU requires retrospective application to all prior periods presented in the financial statements. We are currently evaluating the standard to determine the impact of adoption to our consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures to enhance the transparency and decision usefulness of income tax disclosures. The ASU primarily enhances and expands both the income tax rate reconciliation disclosure and the income taxes paid disclosure. The ASU is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. We are currently evaluating the standard to determine the impact of adoption to our consolidated financial statements and disclosures.

Note 3 - Accounts Receivable

Note 3 - Accounts Receivable	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	3. Accounts Receivable We maintain an allowance for credit losses based on management’s assessment of the collectability of our customer accounts by reviewing customer payment patterns and other relevant factors. We review the adequacy of the allowance for credit losses on a quarterly basis and adjusts the balance as determined necessary. Write-offs are recorded at the time a customer account is deemed uncollectable. The following is a rollforward of our allowance for credit losses (in thousands): As of December 31, 2023 2022 Balance, beginning of period $ 87 $ 89 Provision for credit losses (15 ) 9 Write-offs (8 ) (11 ) Balance, end of period $ 64 $ 87

Note 4 - Accrued Expenses

Note 4 - Accrued Expenses	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. Accrued Expenses Accrued expenses consist of the following (in thousands): As of December 31, 2023 2022 Accrued compensation and employee benefits $ 640 $ 442 Accrued vacation expense 317 409 Accrued taxes 553 771 Accrued shipping expense 113 338 Accrued legal settlement 167 1,150 Other accrued expenses 814 829 Total Accrued Expenses $ 2,604 $ 3,939

Note 5 - Income Taxes

Note 5 - Income Taxes	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	5. Income Taxes The income tax provision consists of the following (in thousands): Year Ended December 31, 2023 2022 Current Federal $ 99 $ 552 State (75 ) 23 Total Current 24 575 Federal 146 (959 ) State 546 428 Total Deferred 692 (531 ) Income Tax Provision $ 716 $ 44 A reconciliation of the effective rate with the federal statutory rate is as follows: Year Ended December 31, 2023 2022 Federal statutory rate 21.0 % 21.0 % State income taxes, net of federal benefit 2.1 % 12.0 % Permanent differences (0.1 )% (0.4 )% Stock based compensation (1.2 )% 0.5 % Federal R&D Credits 3.5 % 8.9 % State R&D Credits 2.9 % 0.0 % Foreign taxes, net of federal benefit 0.0 % 0.0 % Difference in tax rate for carryback claim 0.0 % 0.0 % Change in valuation reserve (48.9 )% (46.2 )% Effective tax rate (20.8 )% (4.2 )% The change in effective tax rate from 2022 to 2023 was primarily driven by the federal and state R&D credits generated during the year. While the amount of credit generated is consistent year over year, the impact on the rate is less significant in 2023 due to the larger book loss incurred. As of December 31, 2023, we had no no The difference between the statutory rate of 21% and our effective tax rate is primarily driven by the benefits related to state taxes and tax credits generated which are offset by the provision related to our valuation allowance. During the year ended December 31, 2023, we recorded a full valuation allowance on the remaining portion of our deferred tax assets. As of December 31, 2023, we had gross deferred tax assets of $3.5 million and gross deferred tax liabilities of $0.9 million, resulting in net deferred tax assets of $2.6 million with an offsetting valuation allowance of $2.6 million. In evaluating the realizability of deferred tax assets, we considered the available positive and negative evidence, including being in a three-year cumulative loss position, projected future pre-tax book income (loss) and other quantitative and qualitative information. As of December 31, 2023, we had no federal net operating loss carryforwards. As of December 31, 2023, we had $1.6 million of state net operating loss carryforwards, of which $1.0 million expire at various dates between 2030 and 2043, and $0.6 million do not expire. As of December 31, 2023, we had no The components of the net deferred tax liabilities included in the accompanying balance sheets are as follows (in thousands): As of December 31, 2023 2022 Deferred Tax Assets Allowance for credit losses $ 15 $ 21 Accrued expenses 154 414 Stock-based compensation 358 381 R&D tax credits 1,193 1,086 Operating lease 488 701 Capitalized research expenses 1,228 404 NOL carryforward 87 72 Gross Deferred Tax Assets 3,523 3,079 Valuation Allowance (2,579 ) (895 ) Deferred Tax Assets After Valuation Allowance 944 2,184 Deferred Tax Liabilities Excess of tax over book depreciation and amortization (447 ) (783 ) Prepaid expenses (70 ) (78 ) Operating lease (427 ) (632 ) Gross Deferred Tax Liabilities (944 ) (1,493 ) Net Deferred Tax Assets $ - $ 691 Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided, if, based upon the weight of available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions (tax contingencies). The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely of being realized upon ultimate settlement. We consider many factors when evaluating and estimating our tax positions and tax benefits, which may require periodic adjustments and which may not accurately forecast actual outcomes. We had immaterial uncertain tax positions at December 31, 2023, and 2022, respectively. We operate within multiple taxing jurisdictions and could be subject to audit in these jurisdictions. These audits may involve complex issues, which may require an extended period of time to resolve. We have provided for our estimated taxes payable in the accompanying financial statements. Our policy is to recognize interest and penalties related to income tax matters as a general and administrative expense, when and if incurred. Interest and penalties for the years ended December 31, 2023, 2022, or 2021 were not material.

Note 6 - Preferred Stock

Note 6 - Preferred Stock	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Preferred Stock [Text Block]	6. Preferred Stock The Board of Directors has the authority to designate authorized preferred shares in one or more series and to fix the relative rights and preferences without vote or action by the stockholders. The Board of Directors has no present plans to designate or issue any shares of preferred stock.

Note 7 - Stock-based Awards

Note 7 - Stock-based Awards	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	7. Stock-Based Awards The 2006 Incentive Plan initially adopted in 2006 provides for grants of options with terms of up to ten On August 17, 2023, we granted Brian Hullinger, in connection with the commencement of his employment as our Chief Executive Officer and President, as an inducement grant outside of the 2006 Incentive Plan, under Nasdaq Listing Rule 5635(c)(4), options to acquire 300,000 shares of common stock. The options have a ten two In addition, on September 21, 2023, we granted Shannon Shoemaker, in connection with the commencement of her employment as our Chief Revenue Officer, grants of options to acquire 120,000 shares of common stock. The options have a ten two The fair value of the SUAs is determined by the closing price on the date of grant. The fair value of options granted with only service conditions are estimated on the date of grant using a Black-Scholes option pricing model. The fair value of options granted with market conditions are estimated at the grant date using a Monte Carlo simulation model. The SUAs and options with only service conditions vest over a period of two four On April 4, 2022, we granted SUAs covering two The following table represents all shares granted by the Company under the 2006 Incentive Plan, and under inducement awards outside of any plan, for the last two years (shares in thousands): Grant Date Type Shares Weighted Average Fair Value September 21, 2023 Options 120 $ 1.66 August 17, 2023 Options 300 $ 2.04 August 17, 2023 SUA 91 $ 4.64 August 12, 2022 SUA 18 $ 6.65 May 20, 2022 SUA 126 $ 6.51 April 4, 2022 SUA 2 $ 7.04 (1) The fair value for the SUAs is the closing price of the Company’s stock on that date. The fair value for options represents the fair value calculated using either the Black-Scholes model or a Monte Carlo simulation. Options have contractual lives of 10 years. The options granted in 2023 have a weighted average grant date fair value of $1.93 per share assuming 1.53 year weighted average estimated service period, 36.4% volatility, 4.7% interest rate and a 0% dividend yield rate. No options were granted during fiscal year ended December 31, 2022. For SUAs granted during fiscal years ended December 31, 2023 and 2022, the weighted average grant date fair values were $4.64 and $6.53, respectively. A summary of the Company’s stock option activity is as follows (in thousands, except price per share): Number of Weighted Average Weighted Aggregate (2) Outstanding, December 31, 2022 508 $ 14.19 5.1 $ 25 Granted 420 $ 4.36 Forfeited (12 ) $ 1.13 Canceled (404 ) $ 14.26 Outstanding, December 31, 2023 512 $ 6.32 8.7 $ - Exercisable, December 31, 2023 90 $ 15.53 4.0 $ - (2) The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market price of the Company’s stock on December 31 of the applicable year exceeded the exercise price of any of the underlying options, multiplied by the number of shares subject to each such option. The closing stock price as of December 31, 2023, and 2022 was $2.96 and $4.90, respectively. A summary of the Company’s stock unit award activity is as follows (in thousands, except price per share): Number of Shares Weighted Average Grant-Date Fair Value per Share (3) Outstanding & Unvested, December 31, 2022 238 $ 6.10 Granted 91 $ 4.64 Converted to common stock (127 ) $ 5.70 Cancelled (11 ) $ 6.54 Forfeited (51 ) $ 5.62 Outstanding & Unvested, December 31, 2023 140 $ 5.23 (3) Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each transaction type. The weighted average fair value is the weighted average share price times the number of shares. The fair value of stock unit award vesting was $786 thousand and $548 thousand for the years ended December 31, 2023, and 2022. The intrinsic value of stock unit awards converted to common stock was based on the stock price on the vesting date and amounted to $670 thousand and $650 thousand for the years ended December 31, 2023, and 2022. As of December 31, 2023, the unamortized fair value of outstanding options and awards was $1.2 million to be amortized over a weighted average period of 1.47 years. The Board of Directors approved the accelerated vesting of 50 thousand SUAs to the former Chief Executive Officer and a certain director upon retirement from such office and from the Board of Directors of the Company during the year ended December 31, 2023. We determined the value of the modifications to be $156 thousand, which is included in stock-based compensation in the accompanying consolidated financial statements, for the year ended December 31, 2023.

Note 8 - Employee Benefit Plan

Note 8 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	8. Employee Benefit Plan The Psychemedics Corporation 401(k) Savings and Retirement Plan (the “401(k) Plan”) is a qualified defined contribution plan in accordance with Section 401(k) of the Internal Revenue Code. All employees over the age of 21 are eligible to make pre-tax contributions up to a specified percentage of their compensation. Under the 401(k) Plan, we may, but are not obligated to, match a portion of the employees’ contributions up to a defined maximum. No

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. Commitments and Contingencies Commitments We lease certain of our facilities and equipment under operating lease agreements expiring on various dates through December 2026. Total minimum lease payments, including scheduled increases, are charged to operations on the straight-line basis over the life of the respective lease. Rent expense was $1.1 million and $1.0 million, in 2023 and 2022, respectively. See Note 10 – “Operating Leases” to the Consolidated Financial Statements included in this Annual Report for commitments remaining under lease agreements. Contingencies In the normal course of business, we are subject to contingencies, such as legal proceedings and claims arising out of our business, that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product liability, contractual claims and tax matters. We recognize accruals for such contingencies when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. These estimates are subject to uncertainties that are difficult to predict and, as such, actual results could vary from these estimates. Settlements On November 2, 2023, we paid $1.2 million to settle the lawsuit Enma Sagastume v. Psychemedics Corporation, Case No. 2:20-CV-06624-DSF, which had been pending in the United States District Court for the Central District of California. This matter is now considered closed. As of December 31, 2023, we paid $334 thousand in connection with a previously disclosed contract dispute regarding strategic negotiations with a shipping carrier. The remaining balance of $167 thousand, is due on or before December 31, 2024, which is included in accrued expenses on the accompanying consolidated balance sheets.

Note 10 - Operating Leases

Note 10 - Operating Leases	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	10. Operating Leases We have five operating leases for office and laboratory space used to conduct business. The exercise of lease renewal options is at our discretion and there are no renewals to extend the lease terms included in our Right-Of-Use (“ROU”) assets and lease liabilities as they are not reasonably certain of exercise. We regularly evaluate the renewal options and when they are reasonably certain of exercise. As most of our leases do not provide an implicit rate, we use the incremental borrowing rate based on the information available at the lease commencement date in determining the net present value (NPV) of the lease payments. The weighted average discount rate used for leases as of December 31, 2023, is 3.9%. The weighted average lease term as of December 31, 2023, is 3.1 years. The operating lease expense for the twelve months ended December 31, 2023, and 2022, was $1.1 million and $1.0 million, respectively. Maturities and balance sheet presentation of our lease liabilities for all operating leases as of December 31, 2023, is as follows (in thousands): 2024 $ 1,061 2025 553 2026 460 Total lease payments 2,074 Less: interest (81 ) Present value of lease liabilities $ 1,993 Current operating lease liabilities $ 1,048 Long-term operating lease liabilities 945 Total $ 1,993

Note 11 - Debt and Other Financ

Note 11 - Debt and Other Financing Arrangements	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	11. Debt and Other Financing Arrangements On March 20, 2014, we entered into an equipment financing arrangement with Banc of America Leasing & Capital, LLC (the “Lender”), which it amended on various dates, most recently on March 23, 2021, including a Master Loan and Security Agreement and related documentation (collectively the “Equipment Loan Arrangement”) which provided us with the ability to finance, at our option, up to $16 million of new and used equipment purchases. Each such purchase financed under the Equipment Loan Arrangement was documented by the execution of an equipment note with a maturity date of 60 months from the applicable loan date. The loans bore interest at the then current 30-day LIBOR rate plus a premium ranging from 1.75% to 3.79%. Principal and interest were payable over the 60 month repayment period. Borrowings under the Equipment Loan Arrangement were secured by a first priority security interest in the equipment acquired with the proceeds of the equipment notes. Under the Equipment Loan Arrangement, we had been subject to a maximum quarterly funded debt to EBITDA ratio and a minimum fixed charge coverage ratio each of which was waived for certain quarters in 2020 and 2021. We were not in compliance with the fixed charge coverage ratio as of December 31, 2023. Subsequent to December 31, 2023, we received a waiver from the lender. Under the Equipment Loan Arrangement, we executed notes on various dates between March 24, 2014, and December 4, 2019 in the aggregate amount of $12.2 million, of which $0.3 million and $0.7 million were repaid in 2023 and 2022, respectively. As of December 31, 2023, the aggregate amount outstanding under the equipment notes was $0.3 million. The weighted average interest rate for these notes for the year ended December 31, 2023, was 3.7% and represented $17 thousand of interest expense. As of December 31, 2023, the weighted average interest rate was 3.8%. The annual principal repayment requirements for debt obligations as of December 31, 2023, are as follows (in thousands): 2024 305 Long-term debt from equipment financing 305 Less current portion of long-term debt from equipment financing (305 ) Long-term debt from equipment financing, net of current portion $ -

Note 12 - Other Income (Expense

Note 12 - Other Income (Expense)	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Other Income and Other Expense Disclosure [Text Block]	12. Other Income/(Expense) Interest expense for the years ended December 31, 2023 and 2022, was $17 thousand and $32 thousand, respectively. There was no

Note 13 - Business Segment Repo

Note 13 - Business Segment Reporting	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	13. Business Segment Reporting We manage our operations as one Year Ended December 31, 2023 2022 Consolidated Revenue: United States $ 21,216 $ 24,509 International 882 731 Total Revenue $ 22,098 $ 25,240

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Dec. 31, 2023
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	Not Applicable
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Risks and Uncertainties [Policy Text Block]	Risks and Uncertainties We are subject to a number of risks and uncertainties similar to those of other companies, such as those associated with the continued expansion of our sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered by us, the economic health of our principal customers , financial and operational risks associated with expansion of testing facilities we use, government regulation (including, but not limited to, FDA regulations, proposed laws and regulations, and delays in implementation of laws and regulations), competition and general economic conditions.
Use of Estimates, Policy [Policy Text Block]	Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates, including those related to bad debts, long-lived asset lives, income tax valuation and share based compensation, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents We consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents. As of December 31, 2023, and 2022, there were no
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property & equipment are recorded at cost. Depreciation and amortization is computed over the estimated useful lives of the assets, using the straight-line method. Repair and maintenance costs are expensed as incurred. The estimated useful lives of the assets are: Computer software 3 to 5 years Office furniture and equipment 3 to 7 years Laboratory equipment 5 to 7 years Leasehold improvements Lesser of estimated useful life or lease term We recorded depreciation and amortization related to property and equipment and capitalized software of $1.7 million, $2.4 million in 2023 and 2022, respectively. We had $613 thousand of capitalized software and equipment that was not placed in service as of December 31, 2023, which is included as a component of computer software on the accompanying consolidated balance sheets.
Research, Development, and Computer Software, Policy [Policy Text Block]	Capitalized Software Development Costs We capitalize costs related to significant software projects developed or obtained for internal use, including costs incurred in a cloud computing arrangement. Costs incurred during the preliminary project work stage or conceptual stage, such as determining the performance requirements, system requirements and data conversion, are expensed as incurred. Costs incurred in the application development phase, such as coding, testing for new software and upgrades that result in additional functionality, are capitalized and are amortized using the straight-line method over the useful life of the software for three five
Other Assets [Policy Text Block]	Other Assets Other assets primarily consist of capitalized legal costs relating to patent applications. We amortize these costs over the lesser of the legal life or estimated useful life of the patent from the date of grant of the applicable patent. The typical life is twenty
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Credit Losses The allowance for credit losses is based on management’s assessment of the ability to collect amounts owed to us by our customers. Management reviews the collectability of our accounts receivable and establishes an allowance for estimated losses that could result from the inability of our customers to make required payments, taking into consideration customer credit history and financial condition, industry and market segment information, credit reports, and economic trends and conditions. We maintain an allowance for potential credit losses but historically has not experienced any significant losses related to individual customers or groups of customers in any particular industry or geographic area.
Revenue [Policy Text Block]	Revenue Recognition We are in the business of performing drug testing services and reporting the results thereof. Our services are primarily drug and alcohol testing for our customers for an agreed-upon fee per unit tested. The revenues are recognized when the drug test is performed and reported to the customer. Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration (none of which is variable) we expect to be entitled to in exchange for those services. We typically invoice customers monthly for services provided and payments are generally due within 30 to 60 days of the invoice date. The table below disaggregates our external revenue by major source (in thousands). For additional revenue detail relating to geographic breakdown of sales, see Note 13 – “Business Segment Reporting” to the Consolidated Financial Statements included in this Annual Report. Year Ended December 31, 2023 2022 Consolidated Revenue: Testing $ 18,661 $ 21,608 Shipping / Collection (hair) 3,316 3,476 Other 121 156 Total Revenue $ 22,098 $ 25,240 Testing Revenue Drug and alcohol tests for drugs of abuse using hair, performed in our forensic laboratory in California, represents our primary service. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (“CCF”) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer. Most tests are completed the same day that the hair specimen is received. Substantially all tests are completed within a few days once received for processing at our laboratory in California. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue. Revenue is measured as the amount of consideration we expect to receive in exchange for providing services. Sales taxes we pay concurrent with revenue-producing activities are excluded from revenue. Shipping and Hair Collection Revenue Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (collectively called the “sample”) to our laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by third parties who we have contracted with. Shipping and hair collection revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test (associated with the shipping or hair collection charge) and availability of test results to the customer. Revenue is measured as the amount of consideration we expect to receive in exchange for providing services. As we control the service before transferring to the customer, we are considered a principal in the transaction, and therefore record revenues on a gross basis, with shipping and hair collection costs in costs of revenues. Other Revenue Other revenue represents several items including: urine testing performed by other labs, medical review officer charges, legal/testifying services, and other miscellaneous charges. The total of all these items is less than 1% of total revenue. The amounts are generally billed to customers as services are performed, which occurs at a specific point-in-time. Practical Expedients and Exemptions We generally expense sales commissions when incurred as they are typically not related to costs to fulfill customer contracts but relate to overall sales targets. These costs are recorded within marketing and selling expense on the accompanying consolidated statements of operations.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses We expense all research and development costs as incurred.
Contingent Liability Reserve Estimate, Policy [Policy Text Block]	Contingencies Loss contingencies from legal proceedings and claims may occur from government investigations, shareholder lawsuits, product liability, contractual claims, tax and other matters. Accruals are recognized when it is probable a liability will be incurred, and the amount of loss can be reasonably estimated. Legal fees are expensed as incurred.
Income Tax, Policy [Policy Text Block]	Income Taxes We account for income taxes using the liability method pursuant to ASC 740, “ Income Taxes
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that potentially subject us to concentrations of credit risk are principally cash and accounts receivable. Our policy is to place our cash in high quality financial institutions. At times, including presently, these deposits may exceed or be exempt from federally insured limits. We do not believe significant credit risk exists with respect to these institutions. Concentration of credit risk with respect to accounts receivable is limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses but historically have not experienced any significant losses related to individual customers or groups of customers in any particular industry or geographic area. We do not require collateral. We have no significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.
Major Customers, Policy [Policy Text Block]	Significant Customers and Concentration of Credit Risk We had no two one
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation We account for equity awards in accordance with ASC 718, “ Compensation Stock Compensation Stock compensation expense by statements of operations account is as follows (in thousands): Year Ended December 31, 2023 2022 Cost of revenues $ 40 $ 63 General & administrative 756 626 Marketing & selling 47 113 Research & development 65 70 Total stock compensation $ 908 $ 872 See Note 7 – “Stock-Based Awards” to the Consolidated Financial Statements included in this Annual Report for additional information relating to our stock plan.
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Net Loss per Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares and dilutive common stock equivalents outstanding during the period. The number of dilutive common stock equivalents outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and the unvested portion of stock unit awards (“SUAs”). Basic and diluted weighted average common shares outstanding are as follows (in thousands): 2023 2022 Weighted average common shares outstanding, basic 5,740 5,626 Dilutive common equivalent shares - - Weighted average common shares outstanding, assuming dilution 5,740 5,626 For the years ended December 31, 2023, and 2022, options to purchase 512 thousand and 508 thousand common shares were outstanding but not included in the dilutive common equivalent share calculation as their effect would have been anti-dilutive. The following outstanding common stock equivalents were not included in the dilutive common equivalent share calculation as their effect would have been anti-dilutive (in thousands): 2023 2022 Options 512 508 SUAs 140 238 652 746
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Measurements The fair values of cash, accounts receivable and accounts payable approximate their carrying values due to their short maturities. The carrying value of long term debt approximates its fair value, as it is based on current market rates at which we could borrow funds with similar terms.
Basis of Presentation and Consolidation, Policy [Policy Text Block]	Basis of Preparation and Consolidation The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries and have been prepared using accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany transactions and balances have been eliminated.
Segment Reporting, Policy [Policy Text Block]	Segment Reporting We manage our operations as one segment, drug testing services. As a result, the financial information disclosed herein materially represents all of the financial information related to our principal operating segment. See Note 13 – “Business Segment Reporting” to the Consolidated Financial Statements included in this Annual Report for geographic breakdown of revenue.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update No. 2016-13, Financial Instruments Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, among other provisions. The ASU is effective for fiscal year periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the ASU requires retrospective application to all prior periods presented in the financial statements. We are currently evaluating the standard to determine the impact of adoption to our consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures to enhance the transparency and decision usefulness of income tax disclosures. The ASU primarily enhances and expands both the income tax rate reconciliation disclosure and the income taxes paid disclosure. The ASU is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. We are currently evaluating the standard to determine the impact of adoption to our consolidated financial statements and disclosures.

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Disaggregation of Revenue [Table Text Block]	Year Ended December 31, 2023 2022 Consolidated Revenue: Testing $ 18,661 $ 21,608 Shipping / Collection (hair) 3,316 3,476 Other 121 156 Total Revenue $ 22,098 $ 25,240
Schedule of Stock Based Compensation Expense [Table Text Block]	Year Ended December 31, 2023 2022 Cost of revenues $ 40 $ 63 General & administrative 756 626 Marketing & selling 47 113 Research & development 65 70 Total stock compensation $ 908 $ 872
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	2023 2022 Weighted average common shares outstanding, basic 5,740 5,626 Dilutive common equivalent shares - - Weighted average common shares outstanding, assuming dilution 5,740 5,626
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2023 2022 Options 512 508 SUAs 140 238 652 746

Note 3 - Accounts Receivable (T

Note 3 - Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Financing Receivable, Current, Allowance for Credit Loss [Table Text Block]	As of December 31, 2023 2022 Balance, beginning of period $ 87 $ 89 Provision for credit losses (15 ) 9 Write-offs (8 ) (11 ) Balance, end of period $ 64 $ 87

Note 4 - Accrued Expenses (Tabl

Note 4 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	As of December 31, 2023 2022 Accrued compensation and employee benefits $ 640 $ 442 Accrued vacation expense 317 409 Accrued taxes 553 771 Accrued shipping expense 113 338 Accrued legal settlement 167 1,150 Other accrued expenses 814 829 Total Accrued Expenses $ 2,604 $ 3,939

Note 5 - Income Taxes (Tables)

Note 5 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended December 31, 2023 2022 Current Federal $ 99 $ 552 State (75 ) 23 Total Current 24 575 Federal 146 (959 ) State 546 428 Total Deferred 692 (531 ) Income Tax Provision $ 716 $ 44
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2023 2022 Federal statutory rate 21.0 % 21.0 % State income taxes, net of federal benefit 2.1 % 12.0 % Permanent differences (0.1 )% (0.4 )% Stock based compensation (1.2 )% 0.5 % Federal R&D Credits 3.5 % 8.9 % State R&D Credits 2.9 % 0.0 % Foreign taxes, net of federal benefit 0.0 % 0.0 % Difference in tax rate for carryback claim 0.0 % 0.0 % Change in valuation reserve (48.9 )% (46.2 )% Effective tax rate (20.8 )% (4.2 )%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2023 2022 Deferred Tax Assets Allowance for credit losses $ 15 $ 21 Accrued expenses 154 414 Stock-based compensation 358 381 R&D tax credits 1,193 1,086 Operating lease 488 701 Capitalized research expenses 1,228 404 NOL carryforward 87 72 Gross Deferred Tax Assets 3,523 3,079 Valuation Allowance (2,579 ) (895 ) Deferred Tax Assets After Valuation Allowance 944 2,184 Deferred Tax Liabilities Excess of tax over book depreciation and amortization (447 ) (783 ) Prepaid expenses (70 ) (78 ) Operating lease (427 ) (632 ) Gross Deferred Tax Liabilities (944 ) (1,493 ) Net Deferred Tax Assets $ - $ 691

Note 7 - Stock-based Awards (Ta

Note 7 - Stock-based Awards (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]	Grant Date Type Shares Weighted Average Fair Value September 21, 2023 Options 120 $ 1.66 August 17, 2023 Options 300 $ 2.04 August 17, 2023 SUA 91 $ 4.64 August 12, 2022 SUA 18 $ 6.65 May 20, 2022 SUA 126 $ 6.51 April 4, 2022 SUA 2 $ 7.04
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Number of Weighted Average Weighted Aggregate (2) Outstanding, December 31, 2022 508 $ 14.19 5.1 $ 25 Granted 420 $ 4.36 Forfeited (12 ) $ 1.13 Canceled (404 ) $ 14.26 Outstanding, December 31, 2023 512 $ 6.32 8.7 $ - Exercisable, December 31, 2023 90 $ 15.53 4.0 $ -
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Number of Shares Weighted Average Grant-Date Fair Value per Share (3) Outstanding & Unvested, December 31, 2022 238 $ 6.10 Granted 91 $ 4.64 Converted to common stock (127 ) $ 5.70 Cancelled (11 ) $ 6.54 Forfeited (51 ) $ 5.62 Outstanding & Unvested, December 31, 2023 140 $ 5.23

Note 10 - Operating Leases (Tab

Note 10 - Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	2024 $ 1,061 2025 553 2026 460 Total lease payments 2,074 Less: interest (81 ) Present value of lease liabilities $ 1,993 Current operating lease liabilities $ 1,048 Long-term operating lease liabilities 945 Total $ 1,993

Note 11 - Debt and Other Fina_2

Note 11 - Debt and Other Financing Arrangements (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Long-Term Debt Instruments [Table Text Block]	2024 305 Long-term debt from equipment financing 305 Less current portion of long-term debt from equipment financing (305 ) Long-term debt from equipment financing, net of current portion $ -

Note 13 - Business Segment Re_2

Note 13 - Business Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Revenue from External Customers by Geographic Areas [Table Text Block]	Year Ended December 31, 2023 2022 Consolidated Revenue: United States $ 21,216 $ 24,509 International 882 731 Total Revenue $ 22,098 $ 25,240

Note 1 - Nature of Business (De

Note 1 - Nature of Business (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents, at Carrying Value	$ 1,964	$ 4,750

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2020 USD ($)
Cash Equivalents, at Carrying Value	$ 0	$ 0
Depreciation, Depletion and Amortization, Nonproduction	1,700	2,400
Property, Plant and Equipment, Net	3,061	$ 4,573
Finite-Lived Intangible Asset, Expected Amortization, Year One	208
Finite-Lived Intangible Asset, Expected Amortization, Year Two	208
Finite-Lived Intangible Asset, Expected Amortization, Year Three	208
Finite-Lived Intangible Asset, Expected Amortization, Year Four	208
Finite-Lived Intangible Asset, Expected Amortization, Year Five	208
Finite-Lived Intangible Asset, Expected Amortization, after Year Five	$ 61
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares	652	746
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares	512	508
Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Number of Major Customers	0	0
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Number of Major Customers	1	1
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Concentration Risk, Percentage	13%	11%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Concentration Risk, Percentage		11%
Patents [Member]
Amortization	$ 62	$ 62
Finite-Lived Intangible Asset, Useful Life		20 years
Legal Cost Capitalized	900	$ 1,100
Legal Cost Capitalized, Amortization	400	500
Legal Cost Capitalized, Net	$ 500		$ 600
Computer Software, Intangible Asset [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Computer Software, Intangible Asset [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Laboratory Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Laboratory Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Capitalized Software and Equipment [Member]
Property, Plant and Equipment, Net	$ 613,000
Software Development [Member]
Software Development Cost Capitalized	127	127
Amortization	$ 150	$ 282
Software Development [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Software Development [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Revenue by Major Source (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 22,098	$ 25,240
Testing [Member]
Revenues	18,661	21,608
Shipping/Collection (Hair) [Member]
Revenues	3,316	3,476
Other Revenue [Member]
Revenues	$ 121	$ 156

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Summary of Stock Compensation Expense by Income Statement Account (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total stock compensation	$ 908	$ 872
Cost of Sales [Member]
Total stock compensation	40	63
General and Administrative Expense [Member]
Total stock compensation	756	626
Selling and Marketing Expense [Member]
Total stock compensation	47	113
Research and Development Expense [Member]
Total stock compensation	$ 65	$ 70

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Basic and Diluted Weighted Average Common Shares Outstanding (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Weighted average common shares outstanding, basic (in shares)	5,740	5,626
Dilutive common equivalent shares (in shares)	0	0
Weighted average common shares outstanding, assuming dilution (in shares)	5,740	5,626

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Share-Based Payment Arrangement, Cost by Plan (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Options (in shares)	652	746
Share-Based Payment Arrangement, Option [Member]
Options (in shares)	512	508
Stock Unit Awards [Member]
Options (in shares)	140	238

Note 3 - Accounts Receivable -

Note 3 - Accounts Receivable - Summary of the Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Balance	$ 87	$ 89
Provision for credit losses	(15)	9
Write-offs	(8)	(11)
Balance	$ 64	$ 87

Note 4 - Accrued Expenses - Sum

Note 4 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accrued compensation and employee benefits	$ 640	$ 442
Accrued vacation expense	317	409
Accrued taxes	553	771
Accrued shipping expense	113	338
Accrued legal settlement	167	1,150
Other accrued expenses	814	829
Total Accrued Expenses	$ 2,604	$ 3,939

Note 5 - Income Taxes (Details

Note 5 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%	21%
Deferred Tax Assets, Gross	$ 3,523	$ 3,079
Deferred Tax Liabilities, Gross	944	1,493
Deferred Tax Assets, Net	2,600
Deferred Tax Assets, Valuation Allowance	2,579	$ 895
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards	0
Tax Credit Carryforward, Amount	0
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	1,600
Operating Loss Carryforwards, Subject to Expiration	1,000
Operating Loss Carryforwards, Not Subject to Expiration	600
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member]
Tax Credit Carryforward, Amount	$ 1,500
Effective Income Tax Rate Reconciliation, Tax Credit, Percent	4.30%
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent	2.90%

Note 5 - Income Taxes - Summary

Note 5 - Income Taxes - Summary of Income Tax Provision (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Federal	$ 99	$ 552
State	(75)	23
Total Current	24	575
Federal	146	(959)
State	546	428
Total Deferred	692	(531)
Income Tax Provision	$ 716	$ 44

Note 5 - Income Taxes - Reconci

Note 5 - Income Taxes - Reconciliation of Effective Rate with Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Federal statutory rate	21%	21%
State income taxes, net of federal benefit	2.10%	12%
Permanent differences	(0.40%)	(0.40%)
Stock based compensation	(1.20%)	0.50%
Federal R&D Credits	(3.50%)	(8.90%)
Foreign taxes, net of federal benefit	0%	(10.90%)
Difference in tax rate for carryback claim	0%	0%
Increase/(decrease) in valuation reserve	(46.20%)	(50.50%)
Effective tax rate	(20.80%)	(4.20%)

Note 5 - Income Taxes - Compone

Note 5 - Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred Tax Assets
Allowance for credit losses	$ 15	$ 21
Accrued expenses	154	414
Stock-based compensation	358	381
R&D tax credits	1,193	1,086
Operating lease	488	701
Capitalized research expenses	1,228	404
NOL carryforward	87	72
Gross Deferred Tax Assets	3,523	3,079
Valuation Allowance	(2,579)	(895)
Deferred Tax Assets After Valuation Allowance	944	2,184
Deferred Tax Liabilities
Excess of tax over book depreciation and amortization	(447)	(783)
Prepaid expenses	(70)	(78)
Operating lease	(427)	(632)
Gross Deferred Tax Liabilities	(944)	(1,493)
Net Deferred Tax Assets	$ 0	$ 691

Note 7 - Stock-based Awards (De

Note 7 - Stock-based Awards (Details Textual) - USD ($)

8 Months Ended

12 Months Ended

Sep. 21, 2023

Aug. 17, 2023

Aug. 12, 2022

May 20, 2022

Apr. 04, 2022

Nov. 11, 2020

Aug. 17, 2023

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2006

May 31, 2021

Jan. 31, 2019

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)

420,000

Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)

$ 4.36

Share Price

$ 1.93

$ 2.96

$ 4.9

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value

$ 786

$ 548,000

Conversion of Stock, Amount Issued

670,000

$ 650,000

Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount

$ 1,200,000

Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)

1 year 5 months 19 days

Stock Unit Award [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period

18,000

125,000

2,000

91,000

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value

$ 4.64

$ 6.53

Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number (in shares)

50,000

Share-Based Payment Arrangement, Accelerated Cost

$ 156,000

Share-Based Payment Arrangement, Option [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate

36.40%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

4.70%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0%

Minimum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period

2 years

Minimum [Member] | Share-Based Payment Arrangement, Option [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)

1 year 6 months 10 days

Maximum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period

4 years

Chief Executive Officer and President [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period

10 years

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)

300,000

Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)

$ 4.64

Chief Executive Officer and President [Member] | Share-Based Payment Arrangement, Tranche One [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period

2 years

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)

100,000

Chief Executive Officer and President [Member] | Share-Based Payment Arrangement, Tranche Two [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)

100,000

Chief Executive Officer and President [Member] | Share-Based Payment Arrangement, Tranche Three [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)

100,000

Chief Revenue Officer [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period

10 years

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)

120,000

Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)

$ 3.66

Chief Revenue Officer [Member] | Share-Based Payment Arrangement, Tranche One [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period

2 years

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)

40,000

Chief Revenue Officer [Member] | Share-Based Payment Arrangement, Tranche Two [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)

40,000

Chief Revenue Officer [Member] | Share-Based Payment Arrangement, Tranche Three [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)

40,000

Incentive Plan 2006 [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period

10 years

Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant

576,000

1,600,000

1,200,000

Note 7 - Stock-based Awards - S

Note 7 - Stock-based Awards - Summary of Shares Granted Under the 2006 Incentive Plan (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2023 $ / shares shares
September 21, 2023 (in shares) | shares	420
September 21, 2023 (in dollars per share) | $ / shares	$ 4.36
September 21, 2023 [Member]
September 21, 2023 (in shares) | shares	120
September 21, 2023 (in dollars per share) | $ / shares	$ 1.66	[1]
August 17, 2023 [Member]
September 21, 2023 (in shares) | shares	300
September 21, 2023 (in dollars per share) | $ / shares	$ 2.04	[1]
August 17, 2023 [Member] | Stock Unit Award [Member]
September 21, 2023 (in shares) | shares	91
September 21, 2023 (in dollars per share) | $ / shares	$ 4.64	[1]
August 12, 2022 [Member] | Stock Unit Award [Member]
September 21, 2023 (in shares) | shares	18
September 21, 2023 (in dollars per share) | $ / shares	$ 6.65	[1]
May 20, 2022 [Member] | Stock Unit Award [Member]
September 21, 2023 (in shares) | shares	126
September 21, 2023 (in dollars per share) | $ / shares	$ 6.51	[1]
April 4, 2022 [Member] | Stock Unit Award [Member]
September 21, 2023 (in shares) | shares	2
September 21, 2023 (in dollars per share) | $ / shares	$ 7.04	[1]
[1]The fair value for the SUAs is the closing price of the Company’s stock on that date. The fair value for options represents the fair value calculated using either the Black-Scholes model or a Monte Carlo simulation. Options have contractual lives of 10 years. The options granted in 2023 have a weighted average grant date fair value of $1.93 per share assuming 1.53 year weighted average estimated service period, 36.4% volatility, 4.7% interest rate and a 0% dividend yield rate. No options were granted during fiscal year ended December 31, 2022. For SUAs granted during fiscal years ended December 31, 2023 and 2022, the weighted average grant date fair values were $4.64 and $6.53, respectively.

Note 7 - Stock-based Awards -_2

Note 7 - Stock-based Awards - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Outstanding, shares (in shares)	508
Outstanding, weighted average exercise price (in dollars per share)	$ 14.19
Outstanding, weighted average remaining contractual life (Year)	5 years 1 month 6 days	6 years 1 month 6 days
Outstanding, aggregate intrinsic value	$ 0	$ 25
September 21, 2023 (in shares)	420
September 21, 2023 (in dollars per share)	$ 4.36
Forfeited, shares (in shares)	(12)
Forfeited, weighted average exercise price (in dollars per share)	$ 1.13
Canceled, shares (in shares)	(404)
Canceled, weighted average exercise price (in dollars per share)	$ 14.26
Outstanding, shares (in shares)	512	508
Outstanding, weighted average exercise price (in dollars per share)	$ 6.32	$ 14.19
Exercisable, shares (in shares)	90
Exercisable, weighted average exercise price (in dollars per share)	$ 15.53
Exercisable, weighted average remaining contractual life (Year)	4 years 10 months 24 days
Exercisable, aggregate intrinsic value	$ 0

Note 7 - Stock-based Awards - N

Note 7 - Stock-based Awards - Nonvested Award Activity (Details) - Stock Unit Award [Member] - $ / shares shares in Thousands					12 Months Ended
		Aug. 12, 2022	May 20, 2022	Apr. 04, 2022	Dec. 31, 2023
Outstanding & Unvested, shares (in shares)					238
Outstanding & Unvested, weighted average grant-date fair value (in dollars per share)	[1]				$ 6.1
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period		18	125	2	91
Granted, weighted average grant-date fair value (in dollars per share)	[1]				$ 4.64
Converted to common stock, shares (in shares)					(127)
Converted to common stock, weighted average grant-date fair value (in dollars per share)	[1]				$ 5.7
Cancelled, shares (in shares)					(11)
Cancelled, weighted average grant-date fair value (in dollars per share)	[1]				$ 6.54
Forfeited, shares (in shares)					(51)
Forfeited, weighted average grant-date fair value (in dollars per share)	[1]				$ 5.62
Outstanding & Unvested, shares (in shares)					140
Outstanding & Unvested, weighted average grant-date fair value (in dollars per share)	[1]				$ 5.23
[1]Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each transaction type. The weighted average fair value is the weighted average share price times the number of shares.

Note 8 - Employee Benefit Plan

Note 8 - Employee Benefit Plan (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0

Note 9 - Commitments and Cont_2

Note 9 - Commitments and Contingencies (Details Textual) - USD ($)			12 Months Ended
	Dec. 31, 2023	Nov. 02, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating Lease, Expense				$ 1,100,000	$ 1,000,000
Enma Sagastume v. Psychemedics Corporation [Member]
Litigation Settlement, Amount Awarded to Other Party		$ 1,200,000
Negotiations With Shipping Carrier [Member]
Payments for Legal Settlements	$ 334
Negotiations With Shipping Carrier [Member] | Forecast [Member]
Payments for Legal Settlements			$ 167

Note 10 - Operating Leases (Det

Note 10 - Operating Leases (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Lease, Weighted Average Discount Rate, Percent	3.90%
Operating Lease, Weighted Average Remaining Lease Term (Year)	3 years 1 month 6 days
Operating Lease, Expense	$ 1.1	$ 1

Note 10 - Operating Leases - Ma

Note 10 - Operating Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
2024	$ 1,061
2025	553
2026	460
Total lease payments	2,074
Less: interest	(81)
Present value of lease liabilities	1,993
Current operating lease liabilities	1,048	$ 1,037
Long-term operating lease liabilities	945	$ 1,938
Total	$ 1,993

Note 11 - Debt and Other Fina_3

Note 11 - Debt and Other Financing Arrangements (Details Textual) - USD ($) $ in Thousands			12 Months Ended		68 Months Ended
	Dec. 02, 2019	Oct. 30, 2017	Dec. 31, 2023	Dec. 31, 2022	Dec. 04, 2019
Interest Expense			$ 17	$ 32
Banc of America Leasing and Capital [Member] | Equipment Loan Arrangement [Member] | Line of Credit [Member]
Interest Expense	$ 16,000		17
Debt Instrument, Term (Month)	60 months
Debt Instrument, Interest Rate, Stated Percentage	3.79%
Proceeds from Issuance of Long-Term Debt					$ 12,200
Repayments of Long-Term Debt			300	$ 700
Long-Term Debt			$ 300
Long-Term Debt, Weighted Average Interest Rate, over Time			3.70%
Debt, Weighted Average Interest Rate			3.80%
Banc of America Leasing and Capital [Member] | Equipment Loan Arrangement [Member] | Line of Credit [Member] | London Interbank Offered Rate [Member]
Debt Instrument, Basis Spread on Variable Rate		1.75%

Note 11 - Debt and Other Fina_4

Note 11 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Less current portion of long-term debt from equipment financing	$ (305)	$ (294)
Long-term debt from equipment financing, net of current portion	0	$ 305
Equipment Loan Arrangement [Member]
2024	305
Long-term debt from equipment financing	305
Less current portion of long-term debt from equipment financing	(305)
Long-term debt from equipment financing, net of current portion	$ 0

Note 12 - Other Income (Expen_2

Note 12 - Other Income (Expense) (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Interest Expense	$ 17	$ 32
Interest Income, Other	0	0
Settlement Expense	$ 507	$ 0

Note 13 - Business Segment Re_3

Note 13 - Business Segment Reporting (Details Textual)	12 Months Ended
	Dec. 31, 2023
Number of Operating Segments	1

Note 13 - Business Segment Re_4

Note 13 - Business Segment Reporting - Revenue by Major Source (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total Revenue	$ 22,098	$ 25,240
UNITED STATES
Total Revenue	21,216	24,509
Non-US [Member]
Total Revenue	$ 882	$ 731